What Do the Trials Say for Catheter Ablation?-CABANA: Putting All the Evidence Together (Presenter: Douglas L. Packer, MD, FHRS)

CABANA: Putting All the Evidence Together (Presenter: Douglas L. Packer, MD, FHRS)

Video Transcription

Video Summary

In this video presentation, Doug Pecker, also known as John Sapp, discusses the findings of the Cabana trial, which compares ablation versus drug therapy for patients with atrial fibrillation (AF). The primary endpoint of the trial was all-cause mortality, with secondary endpoints including disabling stroke, serious bleeding, and cardiac arrest. The trial found that there was no significant difference between ablation and drug therapy in terms of the primary endpoint or all-cause mortality. However, ablation did show a significant reduction in recurrence of AF and a 17% reduction in mortality rates in patients with heart failure. The trial also found that ablation had a positive impact on quality of life and left atrial volume index. The presentation concludes by stating that while the trial had some indeterminate results, overall ablation was shown to be low risk and beneficial for certain patient groups.

Meta Tag

Lecture ID 4304

Location Room 303

Presenter Douglas L. Packer, MD, FHRS

Role Invited Speaker

Session Date and Time May 10, 2019 10:30 AM - 12:00 PM

Session Number S-058

Keywords

Cabana trial

ablation versus drug therapy

atrial fibrillation

all-cause mortality

heart failure